Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 4—April 2011
Dispatch

High Rates of Staphylococcus aureus USA400 Infection, Northern Canada

George R. Golding, Paul N. Levett, Ryan R. McDonald, James Irvine, Brian Quinn, Mandiangu Nsungu, Shirley Woods, Mohammad Khan, Marianna Ofner-Agostini, Michael R. MulveyComments to Author , and the Northern Antibiotic Resistance Partnership
Author affiliations: Author affiliations: National Microbiology Laboratory, Winnipeg, Manitoba, Canada (G.R. Golding, M.R. Mulvey); Saskatchewan Disease Control Laboratory, Regina, Saskatchewan, Canada (P.N. Levett, R.R. McDonald); Population Health Unit, LaRonge, Saskatchewan (J. Irvine, B. Quinn); Northern Intertribal Health Authority, Prince Albert, Saskatchewan (M. Nsungu, S. Woods); Kelsey Trail Health Region, Melfort, Saskatchewan (M. Khan); Public Health Agency Canada, Ottawa, Ontario, Canada (M. Ofner-Agostini); University of Manitoba, Winnipeg, Manitoba (M.R. Mulvey)

Main Article

Table 1

Broth microdilution antimicrobial susceptibilities of select MRSA and MSSA isolates, northern Canada, 2006–2008*

Antimicrobial drug MRSA isolates, n = 379
 MSSA isolates, n = 286
 p value OR (95% CI)
% R MIC range MIC50 MIC90 % R MIC range MIC50 MIC90
Clindamycin 4.2 <0.25–>8 <0.25 <0.25 27.3 <0.25–>8 <0.25 <0.25 <0.001 0.12 (0.06–0.21)
Erythromycin 5.5 <0.25–>8 1 2 28.0 0.5–>8 2 >8 <0.001 0.15 (0.09–0.26)
Vancomycin 0 <0.25–2 1 1 0 0.5–2 1 1 NS –
SXT 0 <0.25–2 <0.25 <0.25 0 <0.25–2 <0.25 <0.25 NS –
Tetracycline 0.3 <2–>16 <2 <2 0 <2 <2 <2 NS –
Ciprofloxacin 2.4 <0.12–>8 0.5 0.5 1.7 0.25–>8 0.5 0.5 NS –
Rifampin 0 <0.25 <0.25 <0.25 0 <0.25 <0.25 <0.25 NS –
Fusidic acid 2.1 <0.06–>8 0.12 0.25 7.7 <0.06–>8 0.25 0.5 0.001 0.26 (0.1–0.62)
Linezolid 0 0.5–4 2 4 0 1–4 4 4 NS –
Gentamicin 1.6 <0.5–>16 <0.5 <0.5 8.0 <0.5–>16 <0.5 1 <0.001 0.18 (0.07–0.48)
Mupirocin 86.5 <0.12–>128 >128 >128 26.9 <0.12–>128 0.5 >128 <0.001 17.46 (11.56–26.43)
Synercid 0 <0.25–0.5 <0.25 0.5 0 <0.25–1 0.5 0.5 NS –
Nitrofurantoin 0 <32 <32 <32 0 <32 <32 <32 NS –

*Values are mg/mL except as indicated. MRSA, methicilllin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus; R, resistant; OR, odds ratio; CI, confidence interval; MIC50, 50% minimum inhibitory concentration; MIC90, 90% inhibitory concentration; SXT, sulfamethoxazole/trimethoprim; NS, not significant.

Main Article

1Members of the Northern Antibiotic Resistance Partnership are listed at the end of this article.

Page created: July 25, 2011
Page updated: July 25, 2011
Page reviewed: July 25, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external